WilmerHale Counsels Aquinnah Pharmaceuticals in $10M Investment From Pfizer and AbbVie

WilmerHale Counsels Aquinnah Pharmaceuticals in $10M Investment From Pfizer and AbbVie

Firm News

Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced that two additional pharmaceutical companies, Pfizer Inc. and AbbVie Inc., have invested in their work to treat Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. This $10 million adds to an earlier $5 million investment, that WilmerHale also handled, made by Takeda Pharmaceuticals in December 2015.

The WilmerHale team counseling Aquinnah Pharmaceuticals included Joshua Fox and Stephanie Singer.

Read Aquinnah Pharmaceuticals' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.